Image from

Stephen Ditmore, contributing writer

When promising clinical trial results were reported for Novavax’ COVID-19 vaccine, top doctors took notice.  Pfizer, Moderna, and J&J completed their clinical trials, beating Novavax to the EUA punch bowl; but as doubts grew that AstraZeneca’s vaccine would ever be authorized here, people supposed Novavax would be next in queue, and there was real enthusiasm that by the time we were ready to contemplate boosters, Novavax could be in American syringes, ready to take the plunge.

Instead, Novavax is going into production at the Serum Institute of India in preparation for distribution in that nation, Indonesia, and The Philippines.   While a protein subunit vaccine is a gift to the world with virtues including storage at common refrigerator temperature, Novavax, inc. is strategically headquartered near our nation’s capital, and got into the COVID-19 vaccine effort with funding from the Coalition for Epidemic Preparedness Innovations (CEPI), and ultimately from Operation Warp Speed.   What happened?  Has there been a falling out between Novavax and the Biden Administration...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee